L. Ares

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.

Robert W. Hsieh, Melissa L. Johnson, J. Yang, 2022, The Lancet. Oncology.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

E. Felip, D. Planchard, N. Chaput, 2018, JAMA oncology.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC.

X. Le, J. Goldman, M. Reck, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti- EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC).

J. Tabernero, J. Soria, B. Markman, 2010 .

Phase 1/2 Study of the CD56‐Targeting Antibody‐Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small‐Cell Lung Cancer Patients With Extensive‐Stage Disease

M. Socinski, F. Kaye, P. Ellis, 2017, Clinical lung cancer.

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

W. Siegert, S. Fosså, S. Culine, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts.

F. Cappuzzo, D. de Ruysscher, D. Ruysscher, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.